Autres langues Genome & Company

Actions

A314130

KR7314130006

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. Autres places de cotation 31/07/2026			Varia. 5j.	Varia. 1 janv.
3 280,00 ^KRW	+9,70%		-12,06%	-52,33%

24/01/24	Genome & Company annonce les résultats positifs de l'essai clinique de phase 2 sur la combinaison de GEN-001 et Bavencio® ? pour le traitement du cancer gastrique Poster présenté à l'ASCO GI	CI
19/05/23	Genome & Company annonce les résultats positifs de l'analyse intermédiaire de l'essai de phase II Gen-001 Plus Avelumab (Bavencio® ?)	CI

Autres langues

13/04	Genome & Company announced that it has received KRW 6.99999414 billion in funding
03/04	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding
13/03	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.
22/09/25	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index
21/08/25	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.
10/07/25	Genome & Company announced that it has received KRW 25.7890592 billion in funding
28/04/25	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors
24/04/25	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors
24/04/25	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding
24/04/25	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.
19/07/24	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.
17/07/24	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.
24/01/24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI
19/05/23	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial
07/04/23	Genome & Company announced that it has received KRW 23 billion in funding from a group of investors
05/04/23	Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors
02/09/22	Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors
18/08/22	Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors
04/03/22	Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc
21/09/21	Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse
20/09/21	Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index
08/09/21	Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.
09/03/21	Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study
25/02/21	Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients
27/10/20	Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001